BNQVL - GALLIUM CITRATE GA 67 INJECTION
- MSDS: BNQVL
- Manufacturer: MALLINCKRODT MEDICAL INC
- Product Name: GALLIUM CITRATE GA 67 INJECTION
- National Stock Number: 6505-00N030958
Product Identification
Product ID:GALLIUM CITRATE GA 67 INJECTION
MSDS Date:01/05/1991
FSC:6505
NIIN:00N030958
MSDS Number: BNQVL
Responsible Party
MARYLAND HEIGHTS, MO 63043
US
Emergency Phone: 314-344-3800 OR 314-539-1600
Info Phone: 314-344-3800 OR 314-539-1600
Cage: FO650
Contractor
Telephone: 314-770-7800/314-895-2000
Cage: FO650
Ingredients
GALLIUM CITRATE GA-67
CAS: 41183-64-6
Fraction By Weight: <0.001%
SODIUM CHLORIDE
CAS: 7647-14-5
RTECS: VZ4725000
Fraction By Weight: <1%
BENZYL ALCOHOL
CAS: 100-51-6
RTECS: DN3150000
Fraction By Weight: <1%
CITRIC ACID, SODIUM SALT; (SODIUM CITRATE (MFR CAS NO.
CAS: 18996-35-5
RTECS: GE7950000
Fraction By Weight: <1%
WATER
CAS: 7732-18-5
RTECS: ZC0110000
Fraction By Weight: >99%
W/LOCAL, STATE & FEDERAL REGULATIONS.
RTECS: 9999999ZZ
CONFORMITY W/REGS APPROP TO THE GOVT AGENCY
RTECS: 9999999ZZ
VIAL CONTAINING THE DRUG SHOULD BE KEPT W/IN ITS
RTECS: 9999999ZZ
CONTENTS WHICH WOULD CAUSE UNNECESSARY EXPOSURE TO
RTECS: 9999999ZZ
INVOLVE LEVELS OF RADIATION EXPOSURE WHICH
RTECS: 9999999ZZ
Hazards
LD50 LC50 Mixture:NONE SPECIFIED BY MANUFACTURER.
Routes of Entry: Inhalation:NO Skin:NO Ingestion:YES
Reports of Carcinogenicity:NTP:NO IARC:NO OSHA:NO
Health Hazards Acute and Chronic:ACUTE:INHAL:GALLIUM DOES NOT EASILY
BECOME AIRBORNE. NOT EXPECTED TO BE A HLTH HAZ VIA INHAL.
INGEST:MAY CAUSE ASYMPTOMATIC PHYSIOLOGICAL UPTAKE BY THYROID GLAND
OR OTHER TISS. SKIN:NOT EXPECTED TO PR DCE ANY ACUTE ADVERSE HLTH
EFTS. EYE:NOADVERSE EFT EXPECTED, BUT MAY CAUSE MECH IRRIT.
CHRONIC:IT IS (EFTS OF OVEREXP)
Explanation of Carcinogenicity:NOT RELEVANT.
Effects of Overexposure:HLTH HAZ:WIDELY ACCEPTED IN THE SCIENTIFIC
COMMUNITY THAT EXPOS TO SUFFICIENT QTYS OF IONIZING RADIA CAN
POTNTLY CAUSE HARMFUL BIOLOGICAL EFTS WHICH INCL CANCER, LEUKEMIA &
GENETIC & TERATOGENIC EFTS. THE HLTH RISKS ASSOC W/CHRONIC RADIA
EXPOS (CANCER, LEUKEMIA, GENETIC & TERATOGENIC EFTS) ARE BELIEVED
TO (ING 10)
Medical Cond Aggravated by Exposure:NO INFORMATION FOUND.
First Aid
First Aid:REMOVE PROMPTLY ANY CONTAM FROM SKIN, EYES OR CLTHG.
INHAL:REMOVE TO FRESH AIR. SUPPORT BRTHG (GIVE O2/ARTF RESP) .
INGEST:NOTIFY RADIA SFTY PERS IMMED. AMT OF MATL INGESTED SHOULD BE
ASSESSED & DOCUMENTED. SKIN:WASH AFFECTED AREA THORO W/SOAP &
WATER UNTIL NO MORE RADIOACTIVITY CAN BE REMOVED. ALWAYS BLOT DRY.
DO NOT ABRADE SKIN. NOTIFY RADIA SFTY PERS. EYE:IF SPLASH OCCURS,
(SUPP DATA)
Fire Fighting
Extinguishing Media:USE ANY MEANS SUITABLE FOR EXTINGUISHING
SURROUNDING FIRE.
Fire Fighting Procedures:WEAR NIOSH/MSHA APPROVED SCBA & FULL
PROTECTIVE EQUIPMENT .
Unusual Fire/Explosion Hazard:NOT CONSIDERED TO BE AN EXPLOSION HAZARD.
Accidental Release
Spill Release Procedures:IF PROD IS RECEIVED IN LEAKING CNDTN OR ANY
LOSS/RELS OF RADIOACTIVE CONTENTS OCCURS, NOTIFY YOUR RADIA SFTY
DEPT & MALLINCKRODT. ALL CLEANUP OPERATIONS SHOULD BE PERFORMED TO
THE STANDARD OPERATING P ROCEDURES (SOP'S) ESTABLISHED FOR YOUR
(SUPP DATA)
Neutralizing Agent:NONE SPECIFIED BY MANUFACTURER.
Handling
Handling and Storage Precautions:STORE AT 15C-30C. HNDLG TIME SHOULD BE
KEPT TO A MIN & APPROP SHIELDING SHOULD BE USED. HNDLG DEVICES SUCH
AS SYRINGE SHIELDS & TONGS SHOULD BE USED.
Other Precautions:STOR & DISP OF PROD SHOULD BE CONTROLLED IN A MANNER
WHICH IS IN COMPLIANCE W/APPROP REGS OF FED OR STATE GOVT AGENCY
AUTHORIZED TO LICENSE USE OF THIS RADIONUCLIDE. RADIOACTIVE DRUGS
MUST BE HANDLED BY QUALIFIED PERS IN (ING 7)
Exposure Controls
Respiratory Protection:NOT EXPECTED TO REQUIRE PERSONAL RESPIRATOR
USAGE. NIOSH/MSHA APPROVED RESPIRATOR APPROPRIATE FOR EXPOSURE OF
CONCERN .
Ventilation:PROPERLY SEALED CONTAINERS ARE NOT EXPECTED TO REQUIRE ANY
SEPCIAL VENTILATION.
Protective Gloves:DISP PLASTIC, LATEX OR RUBBER GLOVES.
Eye Protection:CHEMICAL WORKERS GOGGLES .
Other Protective Equipment:LABCOAT.
Work Hygienic Practices:NO SMOKING, EATING OR DRINKING SHOULD BE
ALLOWED IN ANY AREA WHERE RADIOACTIVE MATERIALS ARE HANDLED OR
STORED.
Supplemental Safety and Health
HMIS(LEVIEN) IN ASSIGNING HCC,NOTES THAT LD50 SUBCUTANEOUS FOR GALLIUM
CITRATE IS 37-2227MG/KG(RTECS 93-3). IS FIRST AID PROC:WASH W/WATER
FOR AT LEAST 15 MINS OR UNTIL NO MORE RADIOACTIVITY CAN BE RE
MOVED. NOTIFY RADIATION SAFETY PERSONNEL. SPILL PROC:FACILITY.
ENSURE COMPLIANCE (ING 6)
Chemical Properties
HCC:T6
Boiling Pt:B.P. Text:212F,100C
Melt/Freeze Pt:M.P/F.P Text:32.0F,0.0C
Solubility in Water:SOLUBLE
Appearance and Odor:CLEAR, COLORLESS, ODORLESS LIQUID IN A 10 ML GLASS
VIAL.
Stability
Stability Indicator/Materials to Avoid:YES
NONE SPECIFIED BY MANUFACTURER.
Stability Condition to Avoid:NONE SPECIFIED BY MANUFACTURER.
Hazardous Decomposition Products:MAY EMIT RADIOACTIVE FUMES CONTAINING
GA-67 WHEN HEATED TO DECOMPOSITION.
Disposal
Waste Disposal Methods:DISPOSAL MUST BE IN ACCORDANCE W/FEDERAL, STATE
& LOCAL REGULATIONS .
Disclaimer (provided with this information by the compiling agencies):
This information is formulated for use by elements of the Department
of Defense. The United States of America in no manner whatsoever,
expressly or implied, warrants this information to be accurate and
disclaims all liability for its use. Any person utilizing this
document should seek competent professional advice to verify and
assume responsibility for the suitability of this information to their
particular situation.